Infectious diseases are largely preventable, yet they continue to pose a significant threat to public health, particularly among vulnerable populations in developing countries. Basic hygiene practices, especially hand and skin hygiene, have been shown to significantly reduce the risk of the cross-transmission of infections, including those caused by multi-drug-resistant organisms. In light of the growing global concern about antimicrobial resistance, there is an urgent need to review and reinforce these practices. This study provides a general overview of the role that hand hygiene practices play in decreasing infectious diseases by conducting a comprehensive review. Multiple online databases, including Google Scholar, Scopus, and Web of Science, were searched using relevant keywords such as “hygiene practices”, “infectious diseases”, “public health”, “Africa”, and “sanitation”. After filtering the search results for relevancy, selected studies were narratively synthesized to present the latest data on hand hygiene and its impact on infectious diseases. Strengthening hand and skin hygiene, along with environmental sanitation and preventive measures, can help reduce the spread of nosocomial infections. By emphasizing the importance of these fundamental hygiene practices, particularly in regions where the burden of infectious diseases is highest, the development of antibiotic-resistant diseases can be prevented, improving patient safety, and enhancing public health outcomes. Adopting comprehensive hygiene policies, including regular handwashing, is crucial for reducing the prevalence of infectious diseases and improving health outcomes in developing countries.

Antiphospholipid syndrome (APS), also known as Hughes syndrome, is a systemic autoimmune disorder characterized by recurrent thrombosis and pregnancy complications, accompanied by the presence of antiphospholipid antibodies (aPLs). These antibodies target anionic phospholipids or protein–phospholipid complexes within cell membranes, contributing to the underlying mechanisms of the disease. Although anticoagulation therapy remains the cornerstone of APS management, it often fails to prevent complications, particularly in obstetric and thrombotic cases. As autoimmune diseases become increasingly linked to alterations in the gut microbiome, this study investigates the complex interaction between gut bacteria and immune modulation in APS. We explore how disruptions in the gut microbiome may influence the development of autoimmune conditions, with a specific focus on APS. By identifying key microorganisms potentially involved in this gut–immune axis, we aim to provide insights into novel preventive and control approaches. Future research should focus on harnessing the gut microbiome to develop more effective treatments that target both the immune system and microbial populations in APS patients.

Background: Food Bioactive Substances (FBS), extra-nutritional constituents found in foods are promising strategies in the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD). Existing clinical studies showed contradictory results regarding their therapeutic effect. This review aimed to evaluate the effectiveness of food-bioactive substances in patients with NAFLD and non-alcoholic steatohepatitis (NASH). Methods: Six controlled databases (PubMed, Embase, Scopus, ProQuest, CINAHL and Cochrane) were searched, yielding 10969 articles. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed, while screening, quality assessment and data extraction of search results were conducted using Covidence. Results: Thirty-two studies were included in the systematic review, while 8 RCTs with 540 patients with NAFLD were included in the meta-analysis. The meta-analysis underscores the effects of the three most studied FBS (silymarin, curcumin and resveratrol) on key cardiovascular and metabolic markers, including BMI, waist circumference, AST, ALT, LDL, HDL, cholesterol and triglycerides of these patients. Overall, FBS showed a statistically significant reduction in BMI (SMD = -0.28; 95% CI: -0.45 to -0.10, p < 0.01), a slight reduction in LDL (SMD = -0.22; p = 0.02), HOMA-IR (SMD = -0.26, 95% CI = -0.51 to -0.02; p = 0.036), total cholesterol level SMD = -0.15 (95% CI: -0.40 to -0.10; I² = 13%; p = 0.33), especially with silymarin showing the greatest statistically significant reduction in HOMA-IR (SMD = -0.16); p = 0.01), Total Cholesterol (SMD = -0.45, p <0.01), AST (SMD = -0.23, p <0.01) Conclusion: Silymarin appeared to be the most promising intervention, particularly for lowering BMI, LDL, cholesterol and triglycerides, but the high variability between studies limits the generalizability of these results

Background: Cholera and COVID-19 represent a dual burden on healthcare systems, especially in low-resource settings. Despite their significant impact, data on their co-occurrence and interaction remain unreliable. This is primarily due to limited and fragmented data availability, which affects our understanding of the relationship between these two diseases. This systematic review aims to address these gaps by summarizing the current state of knowledge and identifying specific data deficiencies. Methods: A comprehensive search was conducted on PubMed, Scopus, and Web of Science. The search was limited to studies published from January 2020 to December 2023. Specific search terms included “cholera and COVID-19 co-infection,” “cholera outbreaks during COVID-19,” and “impact of COVID-19 on cholera.” The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. Results: A total of 18 studies were identified, encompassing a range of geographic locations and study designs. A meta-analysis revealed a strong positive correlation (95% confidence interval, CI=0.80, 0.99) between COVID-19 and cholera coinfection and comorbidity in Africa and Asia. Specifically, the correlation was observed between the frequency of cholera cases and the incidence of COVID-19, highlighting how the pandemic exacerbated cholera outbreaks in certain regions. Conclusions: The findings highlight the essential need for improved data collection and surveillance to better understand and manage the dual burden of cholera and COVID-19. The systematic review also highlights significant publication bias and data limitations, suggesting that future research should focus on addressing these gaps through enhanced data collection methods and rigorous analysis. Recommendations include developing targeted interventions to improve vaccination coverage and water, sanitation, and hygiene (WASH) practices, alongside strategies to counteract misinformation about vaccines. PROSPERO Registration ID: CRD42023485040

Antiphospholipid syndrome (APS) otherwise known as Hughes syndrome is a systemic autoimmune disease typically linked with characteristic features like thrombosis and pregnancy morbidity with the presence of antiphospholipid antibodies (aPLs). Although anticoagulation is the current flagship treatment for APS, there are reports indicating a considerable failure following this regimen in a significant number of obstetric APS and thrombotic APS cases. Antiphospholipid antibodies (aPLs) bind anionic phospholipids or protein-phospholipid complexes within the cell membrane. Here, we gave a general overview of the biology of APS and the human gut microbiome, our current understanding of the gut bacteria-immune axis in autoimmunity focus on the potential link to APS, highlighting the implicated microorganisms in this context, and proposing recommendations on future therapeutic development.

Background: Cholera and COVID-19 represent a dual burden on healthcare systems, especially in low-resource settings. Despite their significant impact, data on their co-occurrence and interaction remain unreliable. This is primarily due to limited and fragmented data availability, which affects our understanding of the relationship between these two diseases. This systematic review aims to address these gaps by summarizing the current state of knowledge and identifying specific data deficiencies. Methods: A comprehensive search was conducted on PubMed, Scopus, and Web of Science. The search was limited to studies published from January 2020 to December 2023. Specific search terms included “cholera and COVID-19 co-infection,” “cholera outbreaks during COVID-19,” and “impact of COVID-19 on cholera.” The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. The Studies were selected based on predefined criteria, including relevance to the topic, quality of the data, and geographical scope. Results: A total of 18 studies were identified, encompassing a range of geographic locations and study designs. A meta-analysis revealed a strong positive correlation (95% confidence interval, CI=0.80, 0.99) between COVID-19 and cholera coinfection and comorbidity in Africa and Asia. Specifically, the correlation was observed between the frequency of cholera cases and the incidence of COVID-19, highlighting how the pandemic exacerbated cholera outbreaks in certain regions. Conclusions: The findings highlight the essential need for improved data collection and surveillance to better understand and manage the dual burden of cholera and COVID-19. The systematic review also highlights significant publication bias and data limitations, suggesting that future research should focus on addressing these gaps through enhanced data collection methods and rigorous analysis. Recommendations include developing targeted interventions to improve vaccination coverage and water, sanitation, and hygiene (WASH) practices, alongside strategies to counteract misinformation about vaccines. PROSPERO Registration ID: CRD42023485040